AU2000278584B2 - Antithrombotic agents - Google Patents

Antithrombotic agents Download PDF

Info

Publication number
AU2000278584B2
AU2000278584B2 AU2000278584A AU2000278584A AU2000278584B2 AU 2000278584 B2 AU2000278584 B2 AU 2000278584B2 AU 2000278584 A AU2000278584 A AU 2000278584A AU 2000278584 A AU2000278584 A AU 2000278584A AU 2000278584 B2 AU2000278584 B2 AU 2000278584B2
Authority
AU
Australia
Prior art keywords
antibody
factor
fragment
tpa
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2000278584A
Other languages
English (en)
Other versions
AU2000278584A1 (en
Inventor
Frank C Barone
Michael N. Blackburn
Giora Z Feuerstein
John R. Toomey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of AU2000278584A1 publication Critical patent/AU2000278584A1/en
Application granted granted Critical
Publication of AU2000278584B2 publication Critical patent/AU2000278584B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2000278584A 2000-05-15 2000-10-05 Antithrombotic agents Ceased AU2000278584B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57143400A 2000-05-15 2000-05-15
US09/571,434 2000-05-15
PCT/US2000/027438 WO2001087339A1 (en) 2000-05-15 2000-10-05 Antithrombotic agents

Publications (2)

Publication Number Publication Date
AU2000278584A1 AU2000278584A1 (en) 2002-02-14
AU2000278584B2 true AU2000278584B2 (en) 2006-11-16

Family

ID=24283688

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2000278584A Ceased AU2000278584B2 (en) 2000-05-15 2000-10-05 Antithrombotic agents
AU7858400A Pending AU7858400A (en) 2000-05-15 2000-10-05 Antithrombotic agents

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU7858400A Pending AU7858400A (en) 2000-05-15 2000-10-05 Antithrombotic agents

Country Status (20)

Country Link
US (1) US20050037006A1 (enExample)
EP (2) EP1282444B1 (enExample)
JP (1) JP2004516236A (enExample)
KR (2) KR20030034071A (enExample)
CN (2) CN101134107A (enExample)
AT (1) ATE345816T1 (enExample)
AU (2) AU2000278584B2 (enExample)
BR (1) BR0015872A (enExample)
CA (1) CA2411369A1 (enExample)
CZ (1) CZ20023778A3 (enExample)
DE (1) DE60032029T2 (enExample)
ES (1) ES2277597T3 (enExample)
HU (1) HU225874B1 (enExample)
IL (1) IL152831A0 (enExample)
MX (1) MXPA02011385A (enExample)
NO (1) NO20025463L (enExample)
NZ (1) NZ522632A (enExample)
PL (1) PL360060A1 (enExample)
WO (1) WO2001087339A1 (enExample)
ZA (1) ZA200209265B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4485806B2 (ja) 2002-03-20 2010-06-23 ユニヴァーシティ オブ メリーランド，ボルチモア 神経系細胞の非選択的陽イオンチャネルおよび脳腫脹を治療する方法
US8980952B2 (en) 2002-03-20 2015-03-17 University Of Maryland, Baltimore Methods for treating brain swelling with a compound that blocks a non-selective cation channel
US7872048B2 (en) 2004-09-18 2011-01-18 University Of Maryland, Baltimore Methods for treating spinal cord injury with a compound that inhibits a NCCa-ATP channel
US10583094B2 (en) * 2004-09-18 2020-03-10 University Of Maryland Therapeutic methods that target the NCCA-ATP channel
CA2674949A1 (en) 2007-01-12 2008-07-24 J. Marc Simard Targeting ncca-atp channel for organ protection following ischemic episode
CA2691199C (en) 2007-06-22 2017-09-12 Marc J. Simard Inhibitors of ncca-atp channels for therapy
CA2700701C (en) 2007-09-26 2020-12-29 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
LT3002298T (lt) * 2007-11-21 2019-12-10 Univ Oregon Health & Science Monokloniniai antikūnai prieš faktorių xi ir jų panaudojimo būdai
US9518128B2 (en) 2011-12-14 2016-12-13 Janssen Pharmaceuticals, Inc. Thrombin-binding antibody molecules
GB201121513D0 (en) * 2011-12-14 2012-01-25 Cambridge Entpr Ltd Thrombin-binding antibody molecules and uses thereof
CN118320078A (zh) * 2016-12-23 2024-07-12 诺华股份有限公司 采用抗因子XI/XIa抗体治疗的方法
US20240018503A1 (en) * 2017-04-27 2024-01-18 Chugai Seiyaku Kabushiki Kaisha Coagulation factor ix with improved pharmacokinetics
EP3617316A4 (en) 2017-04-27 2020-12-23 Chugai Seiyaku Kabushiki Kaisha COAGULATION FACTOR IX WITH IMPROVED PHARMACOKINETICS
CN115448985A (zh) * 2021-06-08 2022-12-09 上海循曜生物科技有限公司 新型抗栓抗体

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2049655C (en) * 1990-09-17 1996-11-12 Akio Odawara Pharmaceutical composition for inhibiting platelet aggregation
MA24512A1 (fr) * 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
WO2000007626A1 (en) * 1998-08-07 2000-02-17 Smithkline Beecham Corporation Use of anti-coagulation factor antibodies as long-lasting protective agents
DK1107996T3 (da) * 1998-08-28 2002-09-16 Genentech Inc Humane anti-faktor IX/IXa-antistoffer

Also Published As

Publication number Publication date
DE60032029D1 (de) 2007-01-04
NZ522632A (en) 2005-05-27
WO2001087339A1 (en) 2001-11-22
HUP0301804A3 (en) 2005-12-28
EP1282444B1 (en) 2006-11-22
HUP0301804A2 (hu) 2003-08-28
DE60032029T2 (de) 2007-05-31
US20050037006A1 (en) 2005-02-17
EP1825864A2 (en) 2007-08-29
AU7858400A (en) 2001-11-26
BR0015872A (pt) 2004-08-03
NO20025463D0 (no) 2002-11-14
KR20030034071A (ko) 2003-05-01
CN1501812A (zh) 2004-06-02
CN101134107A (zh) 2008-03-05
ES2277597T3 (es) 2007-07-16
EP1282444A1 (en) 2003-02-12
ZA200209265B (en) 2003-10-22
EP1282444A4 (en) 2004-06-30
MXPA02011385A (es) 2004-01-26
PL360060A1 (en) 2004-09-06
JP2004516236A (ja) 2004-06-03
HU225874B1 (en) 2007-11-28
CZ20023778A3 (cs) 2003-08-13
CA2411369A1 (en) 2001-11-22
ATE345816T1 (de) 2006-12-15
EP1825864A3 (en) 2007-09-12
KR20070116192A (ko) 2007-12-06
CN100339132C (zh) 2007-09-26
IL152831A0 (en) 2003-06-24
NO20025463L (no) 2003-01-09

Similar Documents

Publication Publication Date Title
US6391299B1 (en) Anti-factor IX/IXa antibodies
AU2016297018B2 (en) A monoclonal antibody inhibitor of factor XIIa
AU2000278584B2 (en) Antithrombotic agents
AU2000278584A1 (en) Antithrombotic agents
US20020136725A1 (en) Antithrombotic agents
US20060057140A1 (en) Anticoagulant agents useful in treatment of thrombosis
US20070190059A1 (en) Antithrombotic agents
US20030124117A1 (en) Combinations of anti-tissue factor antibodies and anticoagulant and/or antiplatelet agents
HK1109339A (en) Antithrombotic agents
HK1107932A (en) Anticoagulant agents useful in treatment of thrombosis
CA2243236A1 (en) Anticoagulant agents useful in treatment of thrombosis
HK1029513B (en) Anticoagulant humanised antibodies against factor ix, for use in the treatment of thrombosis

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired